Pfizer Inc (PFE)

$24.25 +0.20 (0.83%)
Market Cap 137.07B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 7.87
Forward PE 8.07
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 29,190,400
Avg Vol 42,230,012
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 66%
Beta 0.35
Analysts Sell
Price Target $28.98

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
jack1342
jack1342 Jul. 10 at 5:21 AM
$PFE buying 7k more shares tomorrow morning. This is going to bounce soon just like all the pharma stocks the past year.
0 · Reply
Eventsea5
Eventsea5 Jul. 10 at 2:08 AM
$MRNA $NVAX $PFE $VRAX yall good?
1 · Reply
KenFaulkenberry
KenFaulkenberry Jul. 9 at 11:31 PM
$PFE Pfizer (PFE) Stock Analysis Pfizer may appeal to investors seeking reliable income through its attractive dividend and exposure to the long-term growth of the healthcare and biopharma sectors. If the company can successfully replenish revenue through innovation and acquisitions, it could reestablish growth momentum. Its strong financial position and global reach provide a solid foundation for navigating industry headwinds while delivering shareholder value. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of Pfizer (PFE)? https://dividendvaluebuilder.com/pfizer-pfe-dividend-stock-analysis/
0 · Reply
IndyOne
IndyOne Jul. 9 at 10:18 PM
$MRNA The LPN settlement was massive win for Moderna. After the market had time to digest, it was realized that only the $950 million was guaranteed and Arbutus would only get 20%. Moderna up 17% and Arbutus' initial pop fell back. MRNA market cap went up $3 billion. ABUS was up $11.5 million, see original post from ABUS below on March 4th. For Moderna, we are clear and free. NO ROYALTIES, NO FEES OF ANY KIND MOVING FORWARD. The additional payment from Moderna being contemplated has evaporated! DOJ has stepped in and it is now between Arbutus and DOJ. Good luck with the DOJ. Invest in Moderna. Now $PFE and $BNTX really do need to worry and there might be a massive payment coming your way from them . . . Here is the ABUS post I quoted from March 4. You cannot rewrite history. " @ Luckyrebuy $ABUS Follow Market cap moves: MRNA gains 3.15B while ABUS gains 11.5M following settlement. Disgusting! ABUS leadership should face lawsuits for breach of fiduciary duty to its shareholders."
4 · Reply
Mountainmannn
Mountainmannn Jul. 9 at 9:23 PM
$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 9 at 9:22 PM
$SLS $ABBV this $2.6B manipulated mcap will be worth $40B to big pharma $LLY $ABBV $PFE the instant Gps Phase 3 registrational results are announced. $2.6B /$13.5 per share will be worth $40B / $200 per share all day - every day the instant the P3 results are announced. This is why the lowlife liars are paid to beg us to sell and not buy more.
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 8:44 PM
A U.S. appeals court upheld a lower court ruling in favor of AstraZeneca in its patent dispute with Pfizer subsidiary Wyeth over blockbuster lung cancer drug Tagrisso, concluding that the two patents asserted by Wyeth are invalid. The Federal Circuit agreed that the patents lacked sufficient written descriptions and would require undue experimentation for a skilled scientist to reproduce the claimed inventions. Wyeth, which Pfizer acquired in 2009, filed the lawsuit in 2021, alleging that Tagrisso infringed patents related to breast cancer drug Nerlynx, marketed by Puma Biotechnology under a licensing agreement with Pfizer. Although a Delaware jury awarded Wyeth $107.5 million in damages in 2024, the trial judge later overturned that verdict, and the appeals court has now affirmed the decision. The ruling removes a significant legal overhang for AstraZeneca, whose Tagrisso generated more than $7.2 billion in global revenue last year. $AZN $PFE
0 · Reply
jack1342
jack1342 Jul. 9 at 7:59 PM
$PFE people Taking profits last 5 minutes
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 9 at 7:51 PM
$PFE I don't want to sound overly optimistic but I think the market may finally be finished having their way with us and might be letting us slowly craw away on our hands and knees
2 · Reply
LiveSquawk
LiveSquawk Jul. 9 at 6:22 PM
$PFE | Reports Pfizer Fails To Overturn Cancer Drug Patent Cancellation
0 · Reply
Latest News on PFE
Pfizer price target lowered to $26 from $27 at BofA

2026-07-10T10:30:21.000Z - 20 minutes ago

Pfizer price target lowered to $26 from $27 at BofA

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

2026-07-09T18:30:15.000Z - 16 hours ago

Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

AZN

Pfizer price target lowered to $28 from $30 at JPMorgan

2026-07-08T12:15:37.000Z - 1 day ago

Pfizer price target lowered to $28 from $30 at JPMorgan

Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade

2026-07-07T15:54:25.000Z - 2 days ago

Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 3 days ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Pfizer downgraded to Hold from Buy at HSBC

2026-07-06T09:50:29.000Z - 4 days ago

Pfizer downgraded to Hold from Buy at HSBC

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 10 days ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 29, 2026, 1:20 AM EDT - 11 days ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 15 days ago

Pfizer Declares Third-Quarter 2026 Dividend

Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

2026-06-24T18:20:21.000Z - 15 days ago

Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 15 days ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

2026-06-24T15:25:12.000Z - 15 days ago

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 15 days ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 16 days ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 16 days ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 17 days ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

2026-06-22T20:33:17.000Z - 17 days ago

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 17 days ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 17 days ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 21 days ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 22 days ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 4 weeks ago

Pfizer CEO warns German investment at risk over drug pricing policies

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 4 weeks ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 4 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 4 weeks ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 4 weeks ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 4 weeks ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 4 weeks ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 4 weeks ago

Pfizer Slides: Study update

Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 4 weeks ago

Pfizer Press release: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 4 weeks ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 4 weeks ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 5 weeks ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 5 weeks ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 5 weeks ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 5 weeks ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 5 weeks ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 5 weeks ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026, 8:00 AM EDT - 5 weeks ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 11:10 PM EDT - 6 weeks ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:19 PM EDT - 6 weeks ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 6 weeks ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 6 weeks ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 9:00 AM EDT - 7 weeks ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:08 AM EDT - 7 weeks ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026, 5:05 AM EDT - 7 weeks ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 18, 2026, 8:00 AM EDT - 7 weeks ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

jack1342
jack1342 Jul. 10 at 5:21 AM
$PFE buying 7k more shares tomorrow morning. This is going to bounce soon just like all the pharma stocks the past year.
0 · Reply
Eventsea5
Eventsea5 Jul. 10 at 2:08 AM
$MRNA $NVAX $PFE $VRAX yall good?
1 · Reply
KenFaulkenberry
KenFaulkenberry Jul. 9 at 11:31 PM
$PFE Pfizer (PFE) Stock Analysis Pfizer may appeal to investors seeking reliable income through its attractive dividend and exposure to the long-term growth of the healthcare and biopharma sectors. If the company can successfully replenish revenue through innovation and acquisitions, it could reestablish growth momentum. Its strong financial position and global reach provide a solid foundation for navigating industry headwinds while delivering shareholder value. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of Pfizer (PFE)? https://dividendvaluebuilder.com/pfizer-pfe-dividend-stock-analysis/
0 · Reply
IndyOne
IndyOne Jul. 9 at 10:18 PM
$MRNA The LPN settlement was massive win for Moderna. After the market had time to digest, it was realized that only the $950 million was guaranteed and Arbutus would only get 20%. Moderna up 17% and Arbutus' initial pop fell back. MRNA market cap went up $3 billion. ABUS was up $11.5 million, see original post from ABUS below on March 4th. For Moderna, we are clear and free. NO ROYALTIES, NO FEES OF ANY KIND MOVING FORWARD. The additional payment from Moderna being contemplated has evaporated! DOJ has stepped in and it is now between Arbutus and DOJ. Good luck with the DOJ. Invest in Moderna. Now $PFE and $BNTX really do need to worry and there might be a massive payment coming your way from them . . . Here is the ABUS post I quoted from March 4. You cannot rewrite history. " @ Luckyrebuy $ABUS Follow Market cap moves: MRNA gains 3.15B while ABUS gains 11.5M following settlement. Disgusting! ABUS leadership should face lawsuits for breach of fiduciary duty to its shareholders."
4 · Reply
Mountainmannn
Mountainmannn Jul. 9 at 9:23 PM
$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 9 at 9:22 PM
$SLS $ABBV this $2.6B manipulated mcap will be worth $40B to big pharma $LLY $ABBV $PFE the instant Gps Phase 3 registrational results are announced. $2.6B /$13.5 per share will be worth $40B / $200 per share all day - every day the instant the P3 results are announced. This is why the lowlife liars are paid to beg us to sell and not buy more.
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 8:44 PM
A U.S. appeals court upheld a lower court ruling in favor of AstraZeneca in its patent dispute with Pfizer subsidiary Wyeth over blockbuster lung cancer drug Tagrisso, concluding that the two patents asserted by Wyeth are invalid. The Federal Circuit agreed that the patents lacked sufficient written descriptions and would require undue experimentation for a skilled scientist to reproduce the claimed inventions. Wyeth, which Pfizer acquired in 2009, filed the lawsuit in 2021, alleging that Tagrisso infringed patents related to breast cancer drug Nerlynx, marketed by Puma Biotechnology under a licensing agreement with Pfizer. Although a Delaware jury awarded Wyeth $107.5 million in damages in 2024, the trial judge later overturned that verdict, and the appeals court has now affirmed the decision. The ruling removes a significant legal overhang for AstraZeneca, whose Tagrisso generated more than $7.2 billion in global revenue last year. $AZN $PFE
0 · Reply
jack1342
jack1342 Jul. 9 at 7:59 PM
$PFE people Taking profits last 5 minutes
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 9 at 7:51 PM
$PFE I don't want to sound overly optimistic but I think the market may finally be finished having their way with us and might be letting us slowly craw away on our hands and knees
2 · Reply
LiveSquawk
LiveSquawk Jul. 9 at 6:22 PM
$PFE | Reports Pfizer Fails To Overturn Cancer Drug Patent Cancellation
0 · Reply
JBS_84
JBS_84 Jul. 9 at 5:05 PM
$PFE If it holds see you next week around 25 bucks. I say it will.
1 · Reply
fer69
fer69 Jul. 9 at 5:00 PM
$PFE bought back all my covered calls sold when this was around $28 with a gain of 90% … theta indicates not worth holding them … this should higher after ER
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 9 at 4:57 PM
$PFE can’t wait to close red
1 · Reply
Businesspro
Businesspro Jul. 9 at 4:56 PM
$PFE 👀👍 Added more today IMO current support is $23.70-$24 In for a swing
0 · Reply
JBS_84
JBS_84 Jul. 9 at 4:24 PM
$PFE Hope it stays above 24.21. That is the 9 day ema and the 200 hr ema
0 · Reply
ultraviolin
ultraviolin Jul. 9 at 4:20 PM
$CRSP $PFE Will re-enter $CRSP once it drops further
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 4:15 PM
$PFE
0 · Reply
doubleuptwice
doubleuptwice Jul. 9 at 4:13 PM
$PFE avg 23.95 full ported. It’s time now divergence has been rearing
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 4:13 PM
$ELTP $PFE $GME $TSLA $DJT Pfizer and Elite Pharmaceuticals are making headlines as talks of a potential deal or buyout surface. Elite Pharmaceuticals (ELTP) has shown impressive growth in 2026, with a 77% revenue increase and strong operating income gains. Meanwhile, Elite Pharma is actively seeking acquisition or merger opportunities, engaging M&A firms to explore strategic options. With Pfizer’s history of strategic partnerships and acquisitions, a collaboration or buyout could significantly impact the pharmaceutical market. Investors are watching closely as this story develops. TRUMP MAKING IT HAPPEN....... THANK YOU DJT.
1 · Reply
WuTangClam
WuTangClam Jul. 9 at 3:39 PM
$PFE back to 26$ 😊
1 · Reply
ResearchTrends09
ResearchTrends09 Jul. 9 at 3:26 PM
$PFE I will post once again …
0 · Reply
ResearchTrends09
ResearchTrends09 Jul. 9 at 3:25 PM
$PFE don’t ever forget
1 · Reply